What caused RHY.AX stock to jump today?

RHY.AX stock rose **26.67%** on 04 Feb 2026 after heavy volume of **2,755,061** shares. The move was driven by short-term buying in small-cap healthcare names and renewed interest in Rhythm's ColoSTAT commercial potential.

What is Meyka AI's outlook for RHY.AX stock?

Meyka AI rates RHY.AX **59.01/100 (C+, HOLD)**. The forecast model projects a **yearly price of A$0.07239**, implying **-61.90%** versus the current **A$0.19**. Forecasts are model-based projections, not guarantees.

What are the main risks for RHY.AX stock investors?

Main risks include negative earnings, tight liquidity, high valuation multiples (P/S **19.47**, P/B **81.29**), and commercial execution for ColoSTAT. Small-cap volatility can amplify both gains and losses.

When is Rhythm's next earnings or catalyst date?

Rhythm has an earnings announcement scheduled for **20 Feb 2026**. Investors should watch that date for cash runway details, revenue updates, and commercial progress for ColoSTAT.

AU Stocks

RHY.AX stock +26.67% to A$0.19 on 04 Feb 2026 ASX close: volume-led gain

ByHuzaifa Zahoor February 4, 2026February 4, 2026

RHY.AX stock jumped 26.67% to A$0.19 at the ASX close on 04 Feb 2026, driven by heavy trading and momentum into small-cap healthcare names. Volume reached 2,755,061 shares, about 4.27x the average, suggesting short-term buying pressure. The move made Rhythm Biosciences Limited (RHY.AX) a top gainer on the ASX market closed session. We examine the trade drivers, fundamentals, technicals and model forecasts to frame the risk-reward for investors.